This study demonstrates enhanced aqueous solubility of fluorescent probes targeting soluble Aβ aggregates, suggesting potential in Alzheimer's research.
Soluble amyloid β (Aβ) aggregates have attracted attention as therapeutic targets and biomarkers of Alzheimer's disease. We previously reported a fluorescent probe, BAOP-16, which targets soluble Aβ aggregates. However, its limited aqueous solubility has hindered its application in biological assays. In this study, we developed aqueous-soluble fluorescent probes that target soluble Aβ aggregates. Among the synthesized candidates, sBAOP-2-3, which is substituted with two CH2C–Tf2 groups and a diphenyl amino group, exhibited markedly improved aqueous solubility compared with BAOP-16. It also showed a marked increase in fluorescence intensity in the presence of Aβ oligomers, and the highest selectivity for Aβ oligomers over Aβ fibrils. During the aggregation process of Aβ, sBAOP-2-3 detected soluble Aβ aggregates in an early phase. Furthermore, staining experiments using mouse brain sections suggested that sBAOP-2-3 selectively stained soluble Aβ aggregates in mouse brains. These results suggest that sBAOP-2-3 shows promise as a probe for the selective detection of soluble Aβ aggregates in biological systems.
No takes yet. Share an insight, caveat, or question.
Akasaka et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: